
News|Podcasts|August 21, 2023
Pharmacy Focus: Oncology Edition - PARP Inhibitors Are Changing the Game in Prostate Cancer
This month, we spoke with Cassia Griswold, PharmD, a clinical oncology pharmacist at Mayo Clinic Arizona.
Advertisement
This month, we spoke with Cassia Griswold, PharmD, a clinical oncology pharmacist at Mayo Clinic Arizona. Griswold discussed the latest updates from ASCO in PARP inhibitors for prostate cancer, as well as what's on the horizon in this quickly-evolving treatment space.
Interested in learning more? Check out this related content:
FDA Approves New Combination Therapy for BRCA-Positive Metastatic Castration-Resistant Prostate Cancer Image-Guided Adaptive Radiation Treatments May Reduce Short-Term Adverse Effects in Patients With Prostate Cancer Compared to Non-Adaptive Treatments Enzalutamide Combination, Monotherapy Reduced the Risk of Metastasis or Death in High-Risk Patients With Prostate Cancer
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times - Pharmacy Practice News and Expert Insights
1
FDA Initiates Approval of Leucovorin for Patients With Cerebral Folate Deficiency
2
Rapid CAR T Expansion Linked to Delayed Neurotoxicity in Patients Treated With Cilta-Cel
3
Hercessi, Biosimilar to Herceptin, Shows Favorable Efficacy, Safety in Treating HER2+ MBC in Real-World Setting
4
IMS: Shaping the Future of Multiple Myeloma with Anti-CD38 Quadruplets
5